Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Alnylam Pharmaceuticals is conducting an observational study titled NeuroFeeL Study to evaluate Neurofilament Light Chain (NfL) levels as a biomarker in asymptomatic carriers of Transthyretin (TTR) gene variants and patients with hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy. The study aims to assess NfL’s potential for diagnosing, detecting disease onset, monitoring progression, and evaluating treatment response, which could significantly enhance patient management and outcomes.
Intervention/Treatment: The study involves two cohorts: asymptomatic carriers of TTR variants and patients with hATTR amyloidosis with polyneuropathy. Participants will receive standard care as determined by their treating physicians, with no specific study drug administered.
Study Design: This is a single-center, prospective, cohort observational study. It does not involve any allocation or masking, focusing on observing natural disease progression and response to standard care.
Study Timeline: The study began on April 8, 2024, with the latest update submitted on August 25, 2025. These dates are crucial as they indicate the study’s current phase and ongoing recruitment status, which is essential for tracking progress and anticipating results.
Market Implications: The study’s findings could influence Alnylam Pharmaceuticals’ stock performance by potentially validating NfL as a crucial biomarker, enhancing treatment strategies for hATTR amyloidosis. This could improve investor sentiment and position Alnylam favorably against competitors in the amyloidosis treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.